According to the multicenter retrospective study of Axelrad et al. of 2016 [29], the exposure to anti-TNFα agents or a combination of anti-TNFα and AZA were not associated with increased risk of incident cancer compared to other immunosuppressive drugs or non-immunosuppressed patients (HR 0.32 and 0.64, respectively). This evidence concerns the gene TNF and cancer.